Advanced Malignant Tumors research hub
4 indexed studies · 3 currently recruiting
- authorisedHuman Pharmacology (Phase I)- First administration to humans
Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors
This early-stage clinical trial is testing a new drug called BMS-986463 in adults with advanced cancers. These include advanced lung, ovarian, and womb cancers. Researchers want to find out if the drug is safe, what side effects it causes, and what dose works best.
Spain · France · Italy - recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors
This study looks at new ways to treat advanced cancers using a combination of different medications. Researchers want to see how safe these combinations are and how well they work to shrink tumours or stop them from growing.
Italy · France · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors
This early-stage study is looking at a new medicine called BMS-986406 for people with advanced cancers. Researchers want to see if it's safe and how it works, both by itself and with other treatments. It's an important first step in developing new cancer therapies.
Spain · Belgium - recruitingPHASE1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This study is looking into a new treatment, BMS-986488, for advanced cancers. Researchers want to see if it's safe, tolerable, and effective, either on its own or with other medicines, for people whose cancer has spread or can't be removed with surgery.
United States · Australia · Canada